SG Americas Securities LLC cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 87.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,676 shares of the medical research company’s stock after selling 142,134 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $2,091,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its position in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock worth $345,915,000 after buying an additional 3,815,298 shares in the last quarter. Gotham Asset Management LLC increased its position in Charles River Laboratories International by 4,129.0% in the first quarter. Gotham Asset Management LLC now owns 116,298 shares of the medical research company’s stock worth $10,461,000 after buying an additional 113,548 shares in the last quarter. Van Berkom & Associates Inc. increased its position in Charles River Laboratories International by 0.4% in the second quarter. Van Berkom & Associates Inc. now owns 767,913 shares of the medical research company’s stock worth $77,674,000 after buying an additional 2,970 shares in the last quarter. Mutual of America Capital Management LLC increased its position in Charles River Laboratories International by 4.3% in the first quarter. Mutual of America Capital Management LLC now owns 38,427 shares of the medical research company’s stock worth $3,457,000 after buying an additional 1,579 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new position in Charles River Laboratories International during the first quarter worth approximately $506,000. 93.79% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International, Inc. (NYSE:CRL) opened at 105.03 on Friday. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $106.19. The stock’s 50 day moving average is $100.04 and its 200 day moving average is $93.17. The firm has a market cap of $5.00 billion, a P/E ratio of 27.68 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. During the same quarter in the previous year, the firm earned $1.20 EPS. Charles River Laboratories International’s revenue was up 8.1% on a year-over-year basis. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has authorized a share repurchase program on Wednesday, May 10th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Reduces Stake in Charles River Laboratories International, Inc. (CRL)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/26/sg-americas-securities-llc-reduces-stake-in-charles-river-laboratories-international-inc-crl.html.

Several brokerages have recently issued reports on CRL. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a report on Thursday, August 10th. BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Credit Suisse Group reissued a “neutral” rating and set a $95.00 price target (up previously from $89.00) on shares of Charles River Laboratories International in a report on Tuesday, June 6th. Jefferies Group LLC reissued a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, June 14th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $104.00 price target (up previously from $90.00) on shares of Charles River Laboratories International in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $96.94.

In other news, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the transaction, the insider now owns 20,424 shares of the company’s stock, valued at approximately $2,040,561.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Ross Smith sold 2,552 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the sale, the insider now owns 11,671 shares in the company, valued at approximately $783,124.10. The disclosure for this sale can be found here. Insiders have sold a total of 74,945 shares of company stock valued at $7,398,279 in the last three months. 2.20% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.